Home LiteratureArticle Details
PMID: 19574297 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The role of AUF1 in thyroid carcinoma progression.

Endocrine-related cancer ·Vol. 16 ·No. 3 ·2009-09-00 ·Pages 857-71

Trojanowicz B, Brodauf L, Sekulla C, Lorenz K, Finke R, Dralle H, Hoang-Vu C

Abstract

AUF1/heterogeneous nuclear ribonucleoprotein D is an adenylate-uridylate-rich elements (AREs) -binding protein, which regulates the mRNA stability of many genes related to growth regulation, such as proto-oncogenes, growth factors, cytokines, and cell cycle-regulatory genes. Several studies demonstrated AUF1 involvement in the processes of apoptosis, tumorigenesis, and development by its interactions with ARE-bearing mRNAs. We report here that AUF1 may be involved in thyroid carcinoma progression. Investigations on thyroid tissues revealed that cytoplasmic expression of AUF1 in malignant tissues was increased when compared with benign thyroid tissues. In thyroid carcinoma cell lines, AUF1 was mostly detectable in the nucleus; however, in dividing cells, its increased production was also observed in the cytoplasm. We found AUF1 in complexes with ARE-bearing mRNAs, previously described to be crucial for proliferation and cell cycle of thyroid carcinoma. Total or exon-selective knockdown of AUF1 led to growth inhibition accompanied by induction of cell cycle inhibitors and decreased levels of cell cycle promoters. Our data demonstrate the existence of a complex network between AUF1 and mRNAs encoding proteins related to cell proliferation. AUF1 may control the balance between stabilizing and destabilizing effects, both of which are exerted on cell cycle machinery in thyroid carcinoma. Although we cannot exclude participation of other factors, thyroid carcinoma may recruit cytoplasmic AUF1 to disturb the stability of mRNAs encoding cyclin-dependent kinase inhibitors, leading to uncontrolled growth and progression of tumor cells. Thus, AUF1 may be considered as a new, additional marker for thyroid carcinoma.

MeSH Terms
Biomarkers, Tumor/antagonists & inhibitors,genetics,metabolism Carcinoma/genetics,metabolism,pathology Cell Proliferation Disease Progression Down-Regulation/genetics Gene Expression Regulation, Neoplastic/drug effects Gene Knockdown Techniques Genes, cdc Heterogeneous Nuclear Ribonucleoprotein D0 Heterogeneous-Nuclear Ribonucleoprotein D/antagonists & inhibitors,genetics,metabolism,physiology Humans Protein Binding RNA, Messenger/metabolism RNA, Small Interfering/pharmacology Thyroid Gland/metabolism Thyroid Neoplasms/genetics,metabolism,pathology Tumor Cells, Cultured
Chemicals
Biomarkers, Tumor HNRNPD protein, human Heterogeneous Nuclear Ribonucleoprotein D0 Heterogeneous-Nuclear Ribonucleoprotein D RNA, Messenger RNA, Small Interfering
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Trojanowicz Bogusz
AG Experimentelle and Chirurgische Onkologie, Universitätsklinik und Poliklinik für Allgemein-, Viszeral- und Gefässchirurgie, Martin-Luther Universität, Magdeburger Strasse 18, 06097 Halle/S, Germany.
Brodauf Lars
Sekulla Carsten
Lorenz Kerstin
Finke Rainer
Dralle Henning
Hoang-Vu Cuong
Article Info
Journal
Endocrine-related cancer
Abbr.
Endocr Relat Cancer
ISSN
1479-6821
Published
2009-09-00
Epub
2009-00-02
Pages
857-71
Language
English
Region
England
NLM ID
9436481
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com